Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Blood Rev. 2020 Jul;42:100716. doi: 10.1016/j.blre.2020.100716. Epub 2020 May 30.
Blood Rev. 2020.
PMID: 32593470
Free PMC article.
Review.
The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatment refractory and progressive disease, prognosis has been characteristically poor. JAK inhibition with ruxolitinib or fedratinib thera …
The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatmen …
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R.
Kuykendall AT, et al.
Ann Hematol. 2022 Jan;101(1):139-146. doi: 10.1007/s00277-021-04683-w. Epub 2021 Oct 8.
Ann Hematol. 2022.
PMID: 34622316
Clinical Trial.
In conclusion, treatment with imetelstat was associated with longer overall survival compared to BAT (30 vs 12 months, respectively) in closely matched patients with MF after JAK inhibitor failure, warranting further evaluation of imetelstat in this poor-prognosis patient …
In conclusion, treatment with imetelstat was associated with longer overall survival compared to BAT (30 vs 12 months, respectively) in clos …
Item in Clipboard
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C.
Gerds A, et al.
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e463-e468. doi: 10.1016/j.clml.2018.06.025. Epub 2018 Jun 28.
Clin Lymphoma Myeloma Leuk. 2018.
PMID: 30115545
Following cessation of ruxolitinib, all patients received a first re-challenge course with improvement in symptoms and splenomegaly in 92% and 69%, respectively. Of the 4 patients who received a second re-challenge course of ruxolitinib, all had improvements in sple …
Following cessation of ruxolitinib, all patients received a first re-challenge course with improvement in symptoms and splenomegaly i …
Item in Clipboard
Cite
Cite